Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16 HKD | +1.01% | +1.91% | -23.26% |
May. 10 | EU Grants CE Mark to Shanghai Medbot's Laparoscopic Surgical Robot | MT |
Mar. 27 | Shanghai MicroPort MedBot Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.26% | 1.96B | - | ||
+11.73% | 226B | B | ||
+9.53% | 188B | B- | ||
+14.63% | 137B | B- | ||
+27.47% | 108B | A- | ||
-0.04% | 63.19B | A- | ||
+13.73% | 52.26B | B+ | ||
+4.86% | 51B | B+ | ||
+7.72% | 43.89B | A | ||
+7.86% | 38.07B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2252 Stock
- Ratings Shanghai MicroPort MedBot (Group) Co., Ltd.